Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.

Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.

Abstract: Embodiments of the present invention relate to the use of placental alkaline phosphatase, and other members of the alkaline phosphatase family, to enhance protein synthesis in the muscle as well as the survival of non-cancerous differentiated cells in the muscle, adipose and other tissues. The ability of alkaline phosphatase to selectively enhance the survival of healthy cells and increase protein synthesis has many therapeutic applications. The use of alkaline phosphatase may prevent the loss of body weight and muscle mass typically experienced by diseased (such as cancer) or aging patients, or developing fetuses subjected to harmful conditions, or by patients who are treated with a toxic therapy including chemotherapy.

Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.

Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.

Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.

Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase and other members of the alkaline phosphatase family alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of adult or embryonic stem cells and stem cell-derived progenitor cells in vivo.

Abstract: Embodiments of the present invention relate to the use of placental alkaline phosphatase, and other members of the alkaline phosphatase family, to enhance protein synthesis in the muscle as well as the survival of non-cancerous differentiated cells in the muscle, adipose and other tissues. The ability of alkaline phosphatase to selectively enhance the survival of healthy cells and increase protein synthesis has many therapeutic applications. The use of alkaline phosphatase may prevent the loss of body weight and muscle mass typically experienced by diseased (such as cancer) or aging patients, or developing fetuses subjected to harmful conditions, or by patients who are treated with a toxic therapy including chemotherapy.

Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.

Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.

Abstract: Embodiments of the present invention include the in vivo and in vitro use of a family of anticancer heterocyclic compounds containing a quaternary ammonium group as exemplified by the thioxanthone and thioxanthene compounds [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride, or CCompound1, N,N,-diethyl-N-methyl-2-[9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide, or CCompound3, and N,N,N-trimethyl-3-(9H-thioxanthen-9-ylidene)-propane-1-aminium iodide, or CCompound19 to maintain and increase viability of normal endocrine and exocrine pancreatic cells under pathological conditions, such as type 1 and type 2 diabetes, pancreatitis, pancreatic cancer, or during and after islet transplant, or in preparation for transplant of isolated islet cells via (i) direct contact with these cells, and/or via (ii) enhancing survival and proliferation of endogenous or transplanted adult stem cells, and/or via (iii) reducing viability of pancreatic cancer cells.

Abstract: Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds to promote regeneration of bone marrow from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts.

Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase and other members of the alkaline phosphatase family alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of adult or embryonic stem cells and stem cell-derived progenitor cells in vivo.

Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.

Abstract: Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds to promote regeneration of bone marrow from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts.

Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type I and Type II forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. The invention also provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.

Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention maybe used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens maybe effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.

Abstract: Methods and compositions for altering the viability of cells, particularly cancers in animals and humans are disclosed. The compositions of the present invention are formed from a set of components comprising one or more of the following: a dithiocarbonyl, preferably dithiocarbamate, compound; a divalent metal ion; a modulator of cellular glutathione levels; and an inhibitor of the phosphorylation of choline. The compositions described herein induce a relatively selective and rapid effect on the viability of cancer cells by inducing a mixture of apoptotic and necrotic cell death, with the dominant pathway being apoptosis. Particularly preferred active compositions comprise all four components, although combinations of fewer components can be fully effective in certain tumors.

Abstract: Methods and compositions for altering the viability of cells, particularly cancers in animals and humans are disclosed. The compositions of the present invention are formed from a set of components comprising one or more of the following: a dithiocarbonyl, preferably dithiocarbamate, compound; a divalent metal ion; a modulator of cellular glutathione levels; and an inhibitor of the phosphorylation of choline. The compositions described herein induce a relatively selective and rapid effect on the viability of cancer cells by inducing a mixture of apoptotic and necrotic cell death, with the dominant pathway being apoptosis. Particularly preferred active compositions comprise all four components, although combinations of fewer components can be fully effective in certain tumors.